Scilex Holding (SCLX) Net Cash Flow (2020 - 2026)
Scilex Holding (SCLX) recorded quarterly Net Cash Flow of $1.1 million in Q1 2026, down 77.57% quarter-over-quarter from $4.8 million in Q4 2025, and down 57.12% on a YoY basis from $2.5 million in Q1 2025.
Scilex Holding (SCLX) Net Cash Flow (2020 - 2026) Analysis & Trends
Scilex Holding's Net Cash Flow history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 57.12% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $995000.0 (down 67.12% YoY), while the FY2025 annual figure was $2.4 million, up 267.4% from the prior year.
- Net Cash Flow was $1.1 million for Q1 2026 at Scilex Holding, down from $4.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $30.1 million in Q2 2023 to a low of -$33.1 million in Q3 2023.
- Historically, Net Cash Flow has averaged $144529.4 across 5 years, with a median of -$299000.0 in 2022.
- Biggest YoY gain for Net Cash Flow was 9813.22% in 2022; the steepest drop was 11419.18% in 2022.
- A 5-year view of Net Cash Flow shows it stood at -$299000.0 in 2022, then surged by 1019.4% to $2.7 million in 2023, then slumped by 276.21% to -$4.8 million in 2024, then jumped by 199.77% to $4.8 million in 2025, then slumped by 77.57% to $1.1 million in 2026.
- The last three Net Cash Flow figures came in at $1.1 million (Q1 2026), $4.8 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -1.66 Mn |
| Jun 30, 2025 | -1.66 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | 2.75 Mn |
| Dec 31, 2023 | 2.75 Mn |